## **Summary**

## LabPad Evolution Ksmart CRP

Manufacturer Biosynex SA

Supplier in Scandinavia Biosynex Nordic A/S

Launched in Scandinavia November 2022



## Aim

To assess the analytical performance and user-friendliness of CRP measurements with LabPad Evolution when used by the intended users, i.e. health care professionals, in primary health care.

Performance specifications		Conclusion and results
Repeatability	CV ≤10 %	Not fulfilled when used by the intended users. (CV 18,6 – 24,8 %)
Accuracy ≥95 % of the results within the specified limits compared to the average result of the comparison method	±2 mg/L at CRP concentration <10 mg/L	Not fulfilled when used by the intended users.
	±15 % at CRP concentration ≥10 mg/L	(80,6 %)
User-friendliness	A total rating of "Satisfactory"	Not fulfilled.
		The user-friendliness was
		rated <i>intermediate</i> .

## **Additional information**

**Participants** 186 participants from five primary health care centres, coming in with

symptoms of infection where the general practitioner requested a CRP

measurement.

Evaluated method LabPad Evolution Ksmart CRP (immunofluorescence) on fresh capillary

whole blood using three lots of test kits. Intended for professional use.

Comparison method Cobas 8000, c 702 (particle-enhanced immunoturbidimetric assay) on

venous serum samples.

**Bias** An average small positive bias of 0,29 mg/L between LabPad Evolution and

the comparison method was shown.

**Technical error** 0,38 %. The SKUP recommendation of a fraction of  $\leq$ 2 % was

achieved.

A letter with comments from Biosynex Nordic A/S is attached to the report.

Further information about the evaluation and the organisation of SKUP can be found on www.skup.org. This summary is also published in Danish, Norwegian and Swedish at SKUPs website.

Copyright © 2023 SKUP. SKUP is a co-operative commitment of DEKS in Denmark, Equalis in Sweden and Noklus in Norway. The secretariat is located at Noklus in Bergen, Norway.